5c3c4b79-0682-4f19-96aa-071316a354d4
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.370
- ADIPOGENESIS+0.330
- OXIDATIVE_PHOSPHORYLATION+0.330
- FATTY_ACID_METABOLISM+0.310
- IL6_JAK_STAT3_SIGNALING+0.300
- APICAL_SURFACE+0.290
- INFLAMMATORY_RESPONSE+0.280
- UV_RESPONSE_DN+0.280
- ANDROGEN_RESPONSE+0.270
- PEROXISOME+0.230
Top 10 suppressed
- MYC_TARGETS_V2-0.530
- E2F_TARGETS-0.440
- G2M_CHECKPOINT-0.440
- MYC_TARGETS_V1-0.350
- MITOTIC_SPINDLE-0.300
- INTERFERON_ALPHA_RESPONSE-0.270
- UNFOLDED_PROTEIN_RESPONSE-0.250
- DNA_REPAIR-0.200
- MTORC1_SIGNALING-0.150
- P53_PATHWAY-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 830ff04e-ebca-42d8-a018-0a49315640b5 | — | — | 0.814 |
| 2 | BS_ARBQDTT5 | pilocytic astrocytoma | — | 0.809 |
| 3 | C3L-02508 | — | cohortA1 | 0.790 |
| 4 | TCGA-E9-A227-01A-11R-A157-07 | — | A | 0.788 |
| 5 | TCGA-BH-A0DS-01A-11R-A056-07 | — | B | 0.781 |
| 6 | TCGA-78-7162-01A-21R-2066-07 | — | cohortA2 | 0.781 |
| 7 | TCGA-AO-A0JF-01A-11R-A056-07 | — | A | 0.778 |
| 8 | SRR11296843 | — | — | 0.778 |
| 9 | TCGA-FD-A6TI-01A-11R-A32O-07 | — | — | 0.775 |
| 10 | TCGA-A7-A0CG-01A-12R-A056-07 | — | A | 0.772 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.330 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| MYOGENESIS | 0.140 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |